| abstract |
The present disclosure is an anti-CD38 antigen-binding protein, eg, a fully human anti-CD38 IgG class antibody, which changes to their heavy and / or light chain variable regions as compared to their wild-type parent antibodies. Provided are fully human anti-CD38 IgG class antibodies having their respective amino acid sequences. The present disclosure provides engineered CD38-binding proteins that specifically bind to CD38, in particular anti-CD38 variant antibodies, or antigen-binding portions thereof, and their use. The disclosed anti-CD38 antigen-binding proteins and antibodies have improved characteristics compared to the parent antibody, such as binding to improved CD38 antigen, binding to cells expressing improved CD38, and / or. It has been engineered to exhibit higher levels of cytotoxicity. The anti-CD38 variant antibody can cross-react (bind) with cynomolgus monkey CD38. |